SecBot SecBot
6-K ·Filed Aug 24, 2026

GSK

GSK plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001654954-26-007810
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine PDMR sale with no material impact. Monitor for any cluster of insider selling by multiple executives, which would be a more meaningful signal. The sale is not indicative of operational issues at GSK.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$51.78
T+0 close · Aug 24, 2026 · via day close
Latest settled
−2.05%
T+20 · $50.72 · next T+60 in 9h
Vs SPY
−3.35%
α at T+20
Latest observation
−0.27%
T+57 · FF3 residual α
  1. T+0 · Aug 24 $51.78entry
  2. T+1 · 3mo ago +0.56%α +0.24% · $52.07
  3. T+5 · 3mo ago −2.95%α −3.42% · $50.25
  4. T+20 · 8w ago −2.05%α −3.35% · $50.72
  5. T+59 · todayOpen
  6. T+60 · in 9h Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK's US President, Maya Martinez-Davis, sold a total of 44,397 American Depositary Shares (ADS) over two days (Aug 20-21, 2026) at approximately $52.14 per share, for total proceeds of about $2.3 million. This is a routine insider sale by a senior executive and does not signal any change in company fundamentals or strategy.

Key Facts

  • Maya Martinez-Davis, President US of GSK, sold 3,916 ADS on Aug 20, 2026 at $52.14.
  • Maya Martinez-Davis sold 40,481 ADS on Aug 21, 2026 at a weighted average price of $52.1437.
  • Total ADS sold: 44,397, total proceeds approximately $2.3 million.
  • The sales were executed on the New York Stock Exchange and reported via Form 6-K on Aug 24, 2026.

Financial Impact

Total insider sale proceeds of approximately $2.3 million, representing a de minimis fraction of GSK's $106.1B market cap.

Risk Factors

  • Insider selling by a senior US executive could be misinterpreted by the market as a lack of confidence, though the amount is trivial relative to market cap.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007810
Document: 0001654954-26-007810-index-headers.html0001654954-26-007810
Document: 0001654954-26-007810-index.html0001654954-26-007810
Document: 0001654954-26-007810.txt0001654954-26-007810

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 24, 2026